For hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-(BH4-) responsive…. ANDA 210027, held by PH Health. Sapropterin Dihydrochloride.
As of Nov 21, 2026, ANDA 210027 (Sapropterin Dihydrochloride), held by PH Health, was first approved by FDA on Aug 20, 2019, with 3 approved supplements and 0 published complete response letters.
Sapropterin dihydrochloride powder for oral solution is indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-(BH4-) responsive Phenylketonuria (PKU). Sapropterin dihydrochloride powder for oral solution is to be used in conjunction with a Phe-restricted diet.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 20, 2019 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sapropterin Dihydrochloride500MG/PACKET · for solution;oral | Sapropterin Dihydrochloride | Rx |
| Jul 26, 2021 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 9, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 9, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 20, 2019 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters